stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
| Oct '25 | Oct '24 | |
|---|---|---|
Current Ratio |
22.20 | 1.02 |
Net Debt/EBITDA |
1.23 | 0.49 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.43 | 0.48 |
Capex/Depreciation |
(1.08) | — |
Interest Coverage |
(808.65) | (39.02) |
| (105.36%) | 0.00% | |
| (95.43%) | 0.00% | |
ROIC |
(98.33%) | 0.00% |
Return on Tangible Assets |
(55.00%) | (7,490.48%) |
Average Days of Receivables |
0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.35 |
Free Cash Flow per Share |
(0.13) | (0.03) |
Cash per Share |
0.38 | 0.05 |
Shareholders Equity per Share |
0.58 | 0.01 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.58 | 0.01 |
Free Cash Flow |
(1.69) | (0.23) |
Working Capital |
7.12 | 0.01 |
Capital Expenditures |
(0.02) | — |
Net Current Asset Value |
7.12 | (0.09) |
| Other line items | ||
Quick Ratio |
20.35 | 0.92 |
Depreciation/Fixed assets |
1.54 | — |
Cash ROIC |
(13.86%) | (55.03%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.13) | (0.03) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
0.29 | — |
Average Assets |
4.11 | — |
Average Common Equity |
3.72 | — |
Capex to Sales |
0.00 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026